COST-UTILITY ANALYSIS OF LIRAGLUTIDE VERSUS GLIMEPIRIDE AS ADD-ON TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES IN CHINA

被引：1
|
作者：
Gao, L. [1 ]
Li, S. C. [1 ]
机构：
[1] Univ Newcastle, Callaghan, NSW 2308, Australia
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.358
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A663 / A663
页数：1
相关论文
共 50 条
  • [11] Dapagliflozin plus Saxagliptin Add-On vs. Glimepiride Add-On to Metformin in Patients with Poorly Controlled Type 2 Diabetes
    Frias, Juan P.
    Gonzalez-Galvez, Guillermo
    Johnsson, Eva K.
    Maaske, Jill
    Peters, Anne
    DIABETES, 2018, 67
  • [12] Liraglutide significantly improves glycemic control and reduces body weight compared with glimepiride as add-on to metformin in type 2 diabetes
    Nauck, MA
    Hompesch, M
    Filipczak, R
    Le, TDT
    Nielsen, L
    Zdravkovic, M
    Gumprecht, J
    DIABETES, 2004, 53 : A83 - A83
  • [13] Liraglutide as add-on to metformin in type 2 diabetes: significant improvement in glycaemic control with a reduction in body weight compared with glimepiride
    Nauck, M
    Hompesch, N
    Filipczak, R
    Le, TTD
    Nielsen, L
    Zdravkovic, M
    Gumprecht, J
    DIABETOLOGIA, 2004, 47 : A281 - A281
  • [14] Add-On Treatment with Liraglutide Improves Glycemic Control in Patients with Type 2 Diabetes on Metformin Therapy
    Chiefari, Eusebio
    Capula, Carmelo
    Vero, Ada
    Oliverio, Rosa
    Puccio, Luigi
    Liguori, Rossella
    Pullano, Vittorio
    Greco, Manfredi
    Foti, Daniela
    Tirinato, Domenico
    Vero, Raffaella
    Brunetti, Antonio
    DIABETES TECHNOLOGY & THERAPEUTICS, 2015, 17 (07) : 468 - 474
  • [15] COST-EFFECTIVENESS ANALYSIS OF VILDAGLIPTIN VS. GLIMEPIRIDE AS ADD-ON TO METFORMIN IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS IN GREECE
    Kousoulakou, H.
    Kalogeropoulou, M.
    Panitti, E.
    VALUE IN HEALTH, 2015, 18 (07) : A608 - A608
  • [16] Efficacy and Safety of Gemigliptin as Add-on Therapy in Patients with Type 2 Diabetes Inadequately Controlled on Metformin and Glimepiride
    Han, Kyung Ah
    Yu, Jae Myung
    Jang, Hak Chul
    Ahn, Kyu Jeung
    Oh, Takkeun
    Lee, Hyoung Woo
    Lee, Daeho
    Kim, Jae Taek
    Park, Tae Sun
    Nam, Joo Young
    Chung, Choon Hee
    Kim, Byung-Joon
    Park, Seok Won
    Kim, Sung-Ho
    Park, Kyong Soo
    DIABETES, 2016, 65 : A307 - A307
  • [17] Efficacy and safety of gemigliptin as add-on therapy in patients with type 2 diabetes inadequately controlled on metformin and glimepiride
    Kim, S. -H.
    Yu, J.
    Jang, H.
    Song, Y.
    Ahn, K.
    Oh, T.
    Lee, H.
    Lee, D.
    Kim, J.
    Park, T. -S.
    Jeong, C. -H.
    Kim, B. -J.
    Han, K.
    Park, K.
    DIABETOLOGIA, 2016, 59 : S357 - S357
  • [18] Empagliflozin as add-on to metformin in patients with Type 2 diabetes
    Merker, L.
    Haering, H. U.
    Christiansen, A. Vedel
    Roux, F.
    Salsali, A.
    Kim, G.
    Meinicke, T.
    Woerle, H. J.
    Broedl, U. C.
    DIABETIC MEDICINE, 2015, 32 : 89 - 89
  • [19] Efficacy and safety of gemigliptin as add-on therapy in patients with type 2 diabetes inadequately controlled on metformin and glimepiride
    Han, Kyung Ah
    Yu, Jae Myung
    Jang, Hak Chul
    Song, Young Duk
    Ahn, Kyu Jeung
    Oh, Takkeun
    Lee, Hyoung Woo
    Lee, Daeho
    Kim, Jae Taek
    Jeong, Choon-hee
    Kim, Byoung-joon
    Park, Kyong Soo
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S125 - S126
  • [20] Cost-Utility Analysis of Dapagliflozin as an Add-On to Standard Treatment for Patients with Type 2 Diabetes and High Risk of Cardiovascular Disease in Thailand
    Deerochanawong, Chaicharn
    Vareesangthip, Kriengsak
    Piyayotai, Dilok
    Thongsuk, Dittaya
    Pojchaijongdee, Nuch
    Permsuwan, Unchalee
    DIABETES THERAPY, 2021, 12 (07) : 1947 - 1963
12345